Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    IMDC (International Metastatic RCC Database Consortium) Risk Score for RCC

    Determines overall survival in patients treated with systemic therapy.
    Favorite

    INSTRUCTIONS

    Note: this calculator was formerly referred to as the Heng Score for Metastatic Renal Cell Carcinoma Prognosis.

    When to Use
    Pearls/Pitfalls
    Why Use

    Patients with mRCC treated with modern VEGF therapy.

    This score placed subjects with metastatic renal cell carcinoma (mRCC) treated with modern VEGF therapies (e.g. sunitinib) into three survival groups: poor, intermediate, and favorable. Both the derivation and validation are chart review studies; however, both found similar results. Prospective validation is eagerly awaited.

    There are no validated scoring systems for predicting survival in mRCC. Using a score may help sketch categories of survival time better than clinical judgment alone.

    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1
    No
    0
    Yes
    +1

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    The IMDC Risk Score has theoretical advantages over some other scores:

    • A successful validation study.
    • Focus on those receiving modern treatments in common practice.

    The score may be among the most likely to correctly predict survival categories. Several ongoing trials are using this model in prospective studies (e.g. Motzer 2018).

    Management

    We are unaware of validated management algorithms using the score.

    Critical Actions

    The IMDC Risk Score is relevant exclusively to mRCC patients undergoing systemic therapy.

    Dr. Daniel Heng

    About the Creator

    Daniel Heng, MD, MPH, is a staff medical oncologist at the Tom Baker Cancer Center in Calgary, Alberta, and a clinical professor of medicine at the University of Calgary. He holds a masters of public health from Harvard University and has a keen interest in outcomes, prognostic factors, and clinical trials research in kidney, bladder, prostate and testicular cancers. He is the chair of the Southern Alberta Genitourinary Tumor Group.

    To view Dr. Daniel Heng's publications, visit PubMed

    Wanling Xie

    About the Creator

    Wanling Xie, MS, is a biostatistician at the Dana-Farber Cancer Institute in Boston, Massachusetts. She has published and co-published dozens of peer-reviewed studies. Dr. Xie's research is mainly focused on genitourinary cancers, particularly metastatic renal cell carcinoma and prostate cancer.

    To view Wanling Xie's publications, visit PubMed

    Dr. Toni Choueiri

    About the Creator

    Toni Choueiri, MD, is a medical oncologist and the director of the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital in Boston, Massachusetts. He is also co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center and the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School. Dr. Choueiri's research interests include novel therapies and biomarkers in genitourinary malignancies.

    To view Dr. Toni Choueiri's publications, visit PubMed